Glioblastoma is a devastating brain cancer that currently has no cure. Most cancer treatments, such as radiation therapy and chemotherapy drugs temozolomide and gemcitabine kill cancer cells by inflicting damage to the DNA. However, glioblastoma cells have pathways to repair DNA damage, therefore are resistant to cancer treatments. This thesis explores another drug called LY2606368, a CHK1 inhibitor, as a method to sensitise glioblastoma cells to radiation therapy, temozolomide and gemcitabine. Combining radiation therapy, temozolomide or gemcitabine with LY2606368 increased the amount of DNA damage which associated to greater glioblastoma cell death and improved survival of mice models of glioblastoma.
|Qualification||Doctor of Philosophy|
|Award date||18 Oct 2021|
|Publication status||Unpublished - 2021|